ArticleCurrent neuropharmacology2024

Targeting Gut Dysbiosis and Microbiome Metabolites for the Development of Therapeutic Modalities for Neurological Disorders.

Matthew D Wiefels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.